Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Posted
Welltower Inc is an other business based in the US. Welltower shares (HCN) are listed on the NYSE and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$18.6062 - USD$22.4186 |
---|---|
50-day moving average | USD$0 |
Wall St. target price | USD$72.85 |
PE ratio | 41.4444 |
Dividend yield | USD$3.48 (6.61%) |
Earnings per share (TTM) | USD$3.21 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Welltower stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Welltower's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Welltower's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 41x. In other words, Welltower shares trade at around 41x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Welltower's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 10.2. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Welltower's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Welltower's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$2 billion.
The EBITDA is a measure of a Welltower's overall financial performance and is widely used to measure a its profitability.
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | 0% |
Return on equity TTM | 0% |
Profit margin | 0% |
Book value | $36.991 |
Market capitalisation | USD$19.3 billion |
TTM: trailing 12 months
We're not expecting Welltower to pay a dividend over the next 12 months.
Welltower Inc. (NYSE:HCN), an S&P 500 company headquartered in Toledo, Ohio, is driving the transformation of health care infrastructure. The company invests with leading seniors housing operators, post-acute providers and health systems to fund the real estate infrastructure needed to scale innovative care delivery models and improve people's wellness and overall health care experience. Welltower?, a real estate investment trust ("REIT"), owns interests in properties concentrated in major, high-growth markets in the United States, Canada and the United Kingdom, consisting of seniors housing and post-acute communities and outpatient medical properties. More information is available at www.welltower.com.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.